http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Hee Yeon Kim ),( Chang Wook Kim ),( Jin Ah Kim ),( Mi Ju Cheon ),( Chan Ran You ),( Sang Wook Choi ),( Do Seon Song ),( U Im Chang ),( Jin Mo Yang ),( Sung Won Lee ),( Hae Lim Lee ),( Nam Ik Han ),( 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: This study aimed to assess the efficacy of tenofovir (TDF) monotherapy in lamivudine (LAM)-resistant chronic hepatitis B (CHB) patients with a complete virological response to LAM plus adefovir (ADV). Methods: This is an investigator initiated open label, randomized controlled, non-inferiority trial. LAM-resistant CHB patients on LAM plus ADV therapy with undetectable hepatitis B virus (HBV) DNA were randomized (1:1) to TDF or LAM plus ADV and followed with serum biochemistry and HBV DNA every 12 weeks for 96 weeks. The primary endpoint was the proportion of patients with sustained undetectable HBV DNA at week 48. Results: A total of 76 CHB patients including 26 compensated cirrhosis were enrolled in this study. Thirty-eight patients were randomized to TDF and 38 patients to LAM plus ADV arm. There were no significant differences between two groups in baseline characteristics. Three (7.9%) patients in LAM/ADV group and 7 (18.4%) patients in TDF group were HBeAg-positive. Three patients (2 in LAM/ADV group and 1 in TDF group) dropped out of the study before the 48-week follow-up. Two patients achieved HBsAg seroconversion in LAM/ADV group (2/38, 5.3%). HBeAg loss rate at week 48 was 33.3% (1/3) in LAM/ADV group and 14.3% (1/7) in TDF group. The proportion of patients with sustained complete virological response at week 48 was not significantly different between two groups by per protocol analysis (100% vs 100%) as well as intention-to-treat analysis (94.7% in LAM/ADV group vs 97.2% in TDF group). Conclusions: Switching to TDF monotherapy showed a comparable efficacy to continuing combination therapy in LAM-resistant CHB patients with undetectable HBV DNA to LAM plus ADV combination therapy.
Song, Young-Ran,Sung, Su-Kyung,Shin, Eun-Ju,Cho, Chang-Won,Han, Chun-Ji,Hong, Hee-Do MDPI 2018 INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Vol.19 No.9
<P>The edible and medicinal perennial herb <I>Aster scaber</I> is known to have anticancer, antioxidant, and immunomodulatory properties. However, the biological effects of its polysaccharides are not well understood. Here, we aimed to extract novel polysaccharides with enhanced biological properties from <I>Aster scaber</I> using enzyme-assisted methods. Amylase, cellulase, and pectinase were used to extract enzyme-assisted polysaccharide (ASEP)-A, ASEP-C, and ASEP-P, respectively. The yields, physicochemical properties, and immunostimulatory activities of the polysaccharides were investigated and compared with those of hot water extracted polysaccharide (ASWP). The highest yield (3.8%) was achieved for ASEP-P extracted using pectinase digestion. Fourier-transform infrared spectroscopy (FT-IR) and chemical composition analysis revealed that ASWP and three ASEPs were typical acidic heteropolysaccharides, mainly comprising rhamnose, arabinose, galactose, glucose, and galacturonic acid. Immunostimulatory activity assays on RAW264.7 macrophages showed ASEP-P to have the greatest immunostimulatory potential in terms of nitric oxide (NO) and cytokine productions and phagocytic activity. ASEP-P administration improved immune-enhancing effects in normal mice by improving the spleen index and splenic lymphocyte proliferation, and in immunosuppressed mice by modulating lymphocyte proliferation, natural killer (NK) cell activity, and leukocyte counts. The ASEP-P derived from pectinase hydrolysate of <I>Aster scaber</I> demonstrated efficacious immunostimulatory properties and has potential applications as an immune stimulator.</P>
Song-Hee Han,Sung-June Kim,Young Won Yun,Sang Yoon Nam,Hu-Jang Lee,Beom-Jun Lee 한국실험동물학회 2018 Laboratory Animal Research Vol.34 No.1
This study was performed to investigate the effect of a concentrate of fermented wild ginseng root culture (HLJG0701) on memory improvement in the scopolamine (SPL)-induced memory-deficient mouse model. Eight-week-old male ICR mice were used to evaluate the protective effect of HLJG0701 against the SPLinduced memory loss animal model. The Morris water maze test, which measures hippocampus-dependent learning ability, and the Y-maze test, a short-term memory assessment test, were performed and related markers were analyzed. HLJG0701-treated groups displayed significantly reduced acetylcholinesterase activity and increased acetylcholine level compared with the SPL-administered group (SPL-G) (P<0.05). In the Y-maze test, the spontaneous alternation in al HLJG0711-treated groups was significantly increased compared with that in SPL-G (P<0.05). In the Morris water maze test, the escape latency and time spent in the target quadrant in all HLJG0701-treated groups were significantly decreased and increased, respectively, compared with those in SPL-G (P<0.05). In addition, the brain-derived neurotrophic factor level in groups treated with HLJG0701 300 and 600 mg/kg body weight was significantly increased compared with that in SPL-G (P<0.05). These results suggest that the HLJG0701 may protect against memory loss by inhibiting acetylcholinesterase activity and preventing acetylcholine deficiency.
Song, Su-Min,Shin, Jong-Won,de Guzman, Jefferson V.,Kim, Jin,Yu, Hak-Sun,Jha, Bijay Kumar,Kong, Hyun-Hee,Hong, Yeonchul,Chung, Dong-Il Elsevier 2010 Experimental parasitology Vol.125 No.2
<P><B>Abstract</B></P><P><I>Paragonimus westermani</I> is a trematode parasite that causes inflammatory lung disease as well as systemic infections in carnivorous mammals. The interaction of the parasite with host cells and paired worms is initiated by adhesion and plays an important role in parasite proliferation and differentiation. In this study, we isolated a cDNA encoding a <I>P. westermani</I> fasciclin I domain-containing protein (Pwfas-I). The fasiclin-I domain is suggested to be involved in cell adhesion, migration, and differentiation. Immunohistochemical analysis of <I>P. westermani</I> adult worms with polyclonal anti-Pwfas-I serum revealed immunoreactivity in the egg shells and the cells lining the sub-tegumental layer of adult worm throughout the contact regions of the cyst wall and paired worms. Using cell adhesion and spreading assays, we showed that Pwfas-I supports cell adhesion and spreading. Furthermore, we determined that the ανβ5 integrin was a functional receptor for the Pwfas-I. Taken together, these results suggest that Pwfas-I may be functional for the modulation of cell adhesion via binding with ανβ5 integrin in the extracellular matrix of <I>Paragonimus</I>.</P>
( Hee Yeon Kim ),( Chang Wook Kim ),( Jin Ah Kim ),( Mi Ju Cheon ),( Chan Ran You ),( Sang Wook Choi ),( Do Seon Song ),( U Im Chang ),( Jin Mo Yang ),( Sung Won Lee ),( Hae Lim Lee ),( Nam Ik Han ),( 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: This study aimed to investigate the efficacy of tenofovir (TDF) monotherapy in multiple drug-resistant chronic hepatitis B (CHB) patients with a complete virological response to TDF plus entecavir (ETV). Methods: This is an investigator initiated open label, randomized controlled, non-inferiority trial. Multiple drug-resistant CHB patients on TDF plus ETV therapy with undetectable hepatitis B virus (HBV) DNA were randomized (1:1) to TDF or TDF plus ETV and followed with serum biochemistry and HBV DNA every 12 weeks for 96 weeks. The primary endpoint was the proportion of patients with sustained undetectable HBV DNA at week 48. Results: A total of 50 CHB patients including 9 compensated cirrhosis were enrolled in this study. Twenty-five patients were randomized to TDF and 25 patients to TDF plus ETV arm. Baseline characteristics were not statistically different between two groups. Thirteen (52%) patients in TDF group and 13 (52%) patients in TDF/ETV group were HBeAg-positive. One patient in TDF group dropped out of the study before the 48-week follow-up. The proportion of patients with sustained complete virological response at week 48 was not significantly different between two groups by per protocol analysis (100% vs 100%) as well as intention-to-treat analysis (100% in TDF group vs 96% in TDF/ETV group). Conclusions: Switching to TDF monotherapy showed a comparable efficacy to continuing combination therapy in multiple drug-resistant CHB patients with undetectable HBV DNA to TDF plus ETV combination therapy.
( Hee Yeon Kim ),( Chang Wook Kim ),( Sang Wook Choi ),( Do Seon Song ),( U Im Chang ),( Jin Mo Yang ),( Sung Won Lee ),( Hae Lim Lee ),( Nam Ik Han ),( Sun Hong Yoo ),( Jung Hyun Kwon ),( Soon Woo Na 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Hepatocellular carcinoma (HCC) patients often have cirrhosis, and the severity of liver dysfunction influence the prognosis of HCC. Albumin-Bilirubin (ALBI) grade is a recently introduced measurement for hepatic reserve in HCC patients. We aimed to investigate the prognostic value of ALBI grade in advanced HCC patients in a hepatitis B-virus endemic area. Methods: A total of 411 consecutive advanced HCC patients in Child-Pugh A receiving sorafenib monotherapy from September 2008 to October 2017 were evaluated. Overall survival (OS) was assessed using the Kaplan-Meier method and a Cox proportional hazard model. Results: Hepatitis B virus-related HCCs comprised 73.9% (304/411) of enrolled patients. Among 411 enrolled patients, 113 patients (27.5%) were classified as ALBI grade 1 and 298 patients (72.5%) were classified as ALBI grade 2 in baseline. Majority of the patients with ALBI grade 1 (110/113, 97.3%) had a Child-Pugh score of 5. Among patients with ALBI grade 2, 60.7% (181 patients) had a Child-Pugh score of 6. The median OS was 24.5 and 10.8 months for ALBI grade 1 and 2, respectively (P<0.001). Cox regression analysis showed that baseline ALBI grade 2 strongly influenced the mortality of HCC patients receiving sorafenib [Hazard ratio = 2.29 (95% CI: 1.60-3.27, P<0.001)]. Conclusions: ALBI grade could predict the overall survival of advanced HCC patients in Child-Pugh A treated with sorafenib in a hepatitis B virus-endemic area.
A case of umbilical mass as a manifestation of metastatic colon cancer
( Song Hee Han ),( Min Seok Hur ),( Hye In Cheon ),( Byung Gon Choi ),( Hae Jeong Youn ),( Min Jung Kim ),( Nam Kyung Roh ),( Soo Young Kim ),( Yang Won Lee ),( Yong Beom Choe ),( Kyu Joong Ahn ) 대한피부과학회 2016 대한피부과학회 학술발표대회집 Vol.68 No.1
An 80-year-old male presented to our dermatological clinic with 2-month history of a 2.0x2.0 cm sized erythematous papillary nodule protruding from the umbilicus. No other clinical findings were observed except the skin lesion. A 3 mm punch biopsy specimen of the lesion showed, in dermis, predominant glandular structures with atypical tumor cells and large pools of mucin, which suggested adenocarcinoma. The immunohistochemical studies to identify the site of primary tumor revealed CK20 positivity, CDX2 positivity, and GATA3 negativity. According to these findings, the umbilical lesion was diagnosed as metastatic adenocarcinoma, most likely of colon origin. Through some radiological workups including enhanced CT and whole body PET, we found the primary colon cancer with regional lymph node metastasis and peritoneal seeding with direct invasion to umbilicus. Herein we report a patient with an umbilical mass that led to the diagnosis of an occult colon cancer. This report emphasizes the importance of careful evaluation of any umbilical lesion and the need for histologic diagnosis in case of doubt.